Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis (TB) vaccine in infants at risk for TB infection. “We are pleased to be able to tap into our existing HIV/AIDS clinical research infrastructure to help test promising investigational vaccines against TB,” said NIAID Director Anthony S. Fauci, M.D. The sites are funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Phase II proof-of-concept study is testing the safety and effectiveness of an investigational booster TB vaccine developed by Aeras, a Rockville, Md.-based nonprofit organization focused on developing vaccines and other products to prevent TB, and Crucell N.V., a biopharmaceutical company based in the Netherlands. (more…)